Pfizer's CEO identified 2026 as a key catalyst year for future growth through approximately 20 pivotal study starts, while maximizing the value of its $10 billion acquisition of obesity biotech Metsera. The company has identified six priority therapeutic areas—Oncology, Vaccines, Inflammation & Immunology, Rare Diseases, Internal Medicine, and Anti-Infectives—with oncology positioned as a key growth driver amplified by its 2023 acquisition of Seagen's antibody-drug conjugate portfolio.
Cyborg Score Rationale
Pfizer delivered 6% operational revenue growth for its non-COVID portfolio with strong EPS performance, and is executing a robust pipeline strategy with meaningful near-term catalysts. However, revenue represents a 2% operational decline compared to FY24 and a sharp increase in patent expirations looms in the mid-2030s, putting pressure on Pfizer to refill its pipeline.
Top Insights
Pfizer's newly acquired once-monthly GLP-1 obesity candidate PF3994 met its Phase 2b primary endpoint and is expected to enter 10 Phase 3 trials in 2026, signaling major obesity portfolio potential.
Eliquis, Pfizer's best-selling blood thinner co-owned with BMS, posted 8% sales growth to $7.96B in 2025, but faces patent expirations between 2027-2029, underscoring urgency of pipeline diversification.
Oncology shows strength with Padcev growing 22% to $1.94B and Lorbrena achieving blockbuster status with 40% YoY growth, validating the Seagen acquisition strategy.
Pfizer expects 4% operational revenue growth in 2026 (excluding COVID and loss-of-exclusivity products), with approximately 20 pivotal trial starts anticipated to drive future growth.
Named Competitors
Keytruda — Leading checkpoint inhibitor for oncology
Ozempic/Wegovy — Leading GLP-1 therapy for diabetes and obesity
Mounjaro — GLP-1 RA competitor for diabetes and obesity
Eliquis — Blood thinner (co-marketed by Pfizer)
Opdivo — PD-1 checkpoint inhibitor for oncology
Recent Developments
(February 2026) Reaffirmed 2026 guidance with revenues between $59.5B-$62.5B and strong pipeline momentum across oncology, vaccines, and obesity
(December 2025) Acquired Metsera for obesity assets including once-monthly GLP-1 candidate PF3994 with strong Phase 2b efficacy data
(September 2025) Announced positive Phase 3 data for LP.8.1-adapted COVID-19 vaccine with BioNTech showing robust immune response
Open the full interactive Pfizer Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.